trans-sodium-crocetinate has been researched along with Edema* in 3 studies
3 other study(ies) available for trans-sodium-crocetinate and Edema
Article | Year |
---|---|
Oral and ocular administration of crocetin prevents retinal edema in a murine retinal vein occlusion model.
We investigated the effects of oral and ocular administration of crocetin in a murine retinal vein occlusion (RVO) model. Crocetin is a type of carotenoid contained in the fruit of gardenia (. This study was performed on a murine RVO model, which was created by laser irradiation of retinal veins. We evaluated the retinal thickness after the oral administration of crocetin (100 mg/kg) 1 and 6 h before laser irradiation, and immediately, 6 h, 12 h, and 18 h after laser irradiation in the murine RVO model. In addition, we measured the retinal layer thickness after administration of crocetin eye drops (0.03% or 0.10%) immediately, 6 h, and 12 h after laser irradiation. Western blotting of retinal tissue was used to determine the expression levels of matrix metalloproteinase (MMP-9), tumor nuclear factor (TNF-α), and occludin after oral administration of crocetin.. Oral and ocular administration of crocetin improved retinal edema in the murine RVO model. Crocetin administration statistically significantly suppressed overexpression of MMP-9 and TNF-α, and reversed the reduction of occludin.. These findings indicate that crocetin can protect retinal tight junctions by suppressing retinal edema through an anti-inflammatory effect, which suggests that crocetin may be useful for RVO disease. Topics: Administration, Ophthalmic; Administration, Oral; Animals; Carotenoids; Disease Models, Animal; Edema; Inflammation Mediators; Male; Matrix Metalloproteinase 9; Mice; Occludin; Ophthalmic Solutions; Retina; Retinal Vein Occlusion; Tight Junctions; Tumor Necrosis Factor-alpha; Vitamin A | 2019 |
Suppression of NF-κB pathway by crocetin contributes to attenuation of lipopolysaccharide-induced acute lung injury in mice.
Crocetin, a carotenoid compound, has been shown to reduce expression of inflammation and inhibit the production of reactive oxygen species. In the present study, the effect of crocetin on acute lung injury induced by lipopolysaccharide (LPS) was investigated in vivo. In the mouse model, pretreatment with crocetin at dosages of 50 and 100 mg/kg reduced the LPS-induced lung oedema and histological changes, increased LPS-impaired superoxide dismutase (SOD) activity, and decreased lung myeloperoxidase (MPO) activity. Furthermore, treatment with crocetin significantly attenuated LPS-induced mRNA and the protein expressions of interleukin-6 (IL-6), macrophage chemoattractant protein-1 (MCP-1), and tumour necrosis factor-α (TNF-α) in lung tissue. In addition, crocetin at different dosages reduced phospho-IκB expression and NF-κB activity in LPS-induced lung tissue alteration. These results indicate that crocetin can provide protection against LPS-induced acute lung injury in mice. Topics: Acute Lung Injury; Animals; Carotenoids; Chemokine CCL2; Edema; Female; Gene Expression Regulation; I-kappa B Kinase; Interleukin-6; Lipopolysaccharides; Male; Mice; Mice, Inbred ICR; NF-kappa B; Peroxidase; Phosphoproteins; Signal Transduction; Superoxide Dismutase; Tumor Necrosis Factor-alpha; Vitamin A | 2012 |
Inhibition of tumor promotion in benzo[a]pyrene-initiated CD-1 mouse skin by crocetin.
The effects of topical application of crocetin on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced promotion of skin tumors, hyperplasia, hydrogen peroxide, ornithine decarboxylase (ODC) and inflammation were evaluated in female CD-1 mice. Topical application of crocetin (0.2 or 1.0 mumol) with TPA (15 nmol) twice weekly for 20 weeks to mice previously initiated with benzo[a]pyrene (B[a]P) inhibited the number of TPA-induced tumors per mouse by 69 and 81% respectively. Pre-application of the same amount of crocetin also afforded significant protection against TPA-induced hyperplasia in the ear skin. Topical application of crocetin inhibited tumor promoter-caused induction of epidermal ODC activity by TPA (5 nmol). The topical application of crocetin (0.2 or 1.0 mumol) inhibited TPA-induced edema of mouse ears by 76 and 87% respectively. Pretreatment of mouse skin with various amounts of crocetin caused inhibition of hydrogen peroxide and myeloperoxidase production by TPA. These results indicate that crocetin possesses potential as a cancer chemopreventive agent against tumor promotion. Topics: Animals; Anticarcinogenic Agents; Benzo(a)pyrene; Carotenoids; Edema; Enzyme Induction; Female; Hydrogen Peroxide; Hyperplasia; Mice; Mice, Inbred Strains; Ornithine Decarboxylase; Peroxidase; Skin; Skin Neoplasms; Tetradecanoylphorbol Acetate; Vitamin A | 1995 |